Skip to main content

Drug Interactions between lovotibeglogene autotemcel and peginesatide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

peginesatide lovotibeglogene autotemcel

Applies to: peginesatide and lovotibeglogene autotemcel

GENERALLY AVOID: Erythropoiesis-stimulating agents (ESAs) may interfere with the efficacy and manufacturing of the autologous hematopoietic stem cell-based gene therapy, lovotibeglogene autotemcel. The exact mechanism has not been fully described in product labeling or clinical studies. Data regarding the use of ESAs between apheresis and myeloablative conditioning as well as after the lovotibeglogene autotemcel infusion are unavailable.

MANAGEMENT: The manufacturer of lovotibeglogene autotemcel recommends discontinuing the use of erythropoiesis-stimulating agents at least 2 months prior to the initiation of HSC mobilization. The manufacturer does not provide guidance on the use of erythropoiesis-stimulating agents after apheresis and before myeloablative conditioning, or after the lovotibeglogene autotemcel infusion.

References (1)
  1. (2023) "Product Information. Lyfgenia (lovotibeglogene autotemcel)." bluebird bio

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer